Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SFDA Considers Importing Semi-Finished Blood Products

This article was originally published in PharmAsia News

Executive Summary

Due to blood plasma shortages, China's major blood product companies often operate below capacity, leading to severe supply shortages on blood products. Hualan Biological Engineering, China's largest blood product producer, which accounts for 40 percent of the domestic market, has suspended output for four months in the past three quarters, further worsening the dire status. Responding to the situation, China's State FDA revealed that it is considering allowing the import of semi-finished blood products to ease local blood plasma shortages. Because blood products are linked to national security, China has no relevant policies and criteria for import and export. Thus, preparatory groundwork will be needed for semi-finished product imports. (Click here for more - Chinese Language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC067189

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel